$12.88-1.2%Nov 13 close
Figures through September 30, 2026, from the 6-K filed November 12, 2026
The quarter ending September 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $3.6M | $5.4M | -34.19% |
| Profit | -$6M | -$2.7M | -125.75% |
| Profit per share | -$0.65 | -$1.23 | +47.15% |
| Free Cash Flow | -$8.5M | -$4.3M | -97.36% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Mediwound Ltd. reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We continue to execute our strategic plan, with the EscharEx Phase III VALUE trial as our top priority. We are on track to complete the pre-specified interim sample size reassessment and full enrollment by the end of the first quarter of 2027,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
MediWound Ltd. (Nasdaq: MDWD) is a global biotechnology company pioneering enzymatic, non-surgical therapies for tissue repair. The Company’s FDA-approved biologic, NexoBrid ® , is indicated for the enzymatic removal of eschar in thermal burns and is marketed in the United States, the European Union, Japan, and additional international markets. MediWound’s late-stage pipeline product, EscharEx ® , is an investigational therapy for the debridement of chronic wounds, with the potential to become, if approved, a new standard of care in wound management.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from the 6-K Mediwound Ltd. filed on November 12, 2026 with its results; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.